Zafgen Inc (NASDAQ:ZFGN) shares saw an uptick in trading volume on Thursday following a stronger than expected earnings report. 722,950 shares were traded during trading, an increase of 169% from the previous session’s volume of 268,353 shares.The stock last traded at $11.49 and had previously closed at $10.15.
The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.04.
Several research firms have weighed in on ZFGN. Zacks Investment Research upgraded shares of Zafgen from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. Wedbush began coverage on shares of Zafgen in a research note on Thursday, August 2nd. They issued an “outperform” rating and a $14.00 price objective on the stock. Finally, BidaskClub lowered shares of Zafgen from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $15.25.
The company has a market capitalization of $370.26 million, a P/E ratio of -6.05 and a beta of -0.23. The company has a current ratio of 8.42, a quick ratio of 8.42 and a debt-to-equity ratio of 0.36.
COPYRIGHT VIOLATION WARNING: “Zafgen (ZFGN) Sees Strong Trading Volume on Earnings Beat” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.wkrb13.com/2018/11/08/zafgen-zfgn-sees-strong-trading-volume-on-earnings-beat.html.
Zafgen Company Profile (NASDAQ:ZFGN)
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Article: What are earnings reports?
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.